Business
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).CTX-8371 was generally well tolerated with no observed dose limiting toxici
About this update from Compass Therapeutics, Inc.
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced a poster presentation of data from the Phase 1 study of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies treated in the post-checkpoint inhibitor setting will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL. “We are pleased to share the initial clinical data from the dose escalation portion of our ongoing Phase 1 study of CTX-8371 in patients with advanced malignancies treated in the post-checkpoint inhibitor setting at ASCO,” said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. “Based on the deep, confirmed, and durable responses observed in patients with NSCLC, TNBC and HL, as well as the favorable safety profile, we have initiated cohort expansions in patients with these three malignancies and anticipate reporting additional data in the fourth quarter of 2026.” Details of the presentation are as follows: Title: Phase 1 Dose Escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition Presenter: Judy S Wang, MD; Florida Cancer Specialists/Sarah Cannon Research Institute- Sarasota, Sarasota, FL Date & Time: May 30, 2026 at 1:30-4:30 pm CT Session: Developmental Therapeutics—Immunotherapy Abstract number: 2629 Poster Board: 419 Location: McCormick Place Convention Center, Hall A Data highlights from the poster presentation include: A copy of the presentation materials can be accessed on the Compass website at https://www.compasstherapeutics.com/pipeline once the presentation has concluded. About Compass TherapeuticsCompass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways t...
View stock analysis, news, and events for Compass Therapeutics, Inc.